Chronic obstructive pulmonary disease (COPD), a general airway disease, is featured by progressive and chronic immunoreaction in the lung. Increasing evidences have showed that cigarette smoking is the main reason in the COPD progression, and human pulmonary microvascular endothelial cell (HPMEC) apoptosis often be observed in COPD, while its pathogenesis is not yet fully described. Upregulation of long noncoding RNA (lncRNA) maternally expressed gene 3 (MEG3) was observed in COPD patients, but the specific mechanism of lncRNA MEG3 in COPD remains unknown. The objective of this research was to explore the role of lncRNA MEG3 in cigarette smoke extract (CSE)-induced HPMECs.
Background
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease featured by irreversible debility of lung function [1] . As a main global health disease, COPD has been predicted to become the fourth primary causing death worldwide by 2020 [2] . Plenty of evidence have demonstrated that many elements were participated in the progression of COPD, such as genetic susceptibility [3] , environmental risk [4] and abnormal inflammatory response [5] . Cigarette smoking, one of the predominant risk factors of COPD, may result in increasing cell apoptosis, damaging endothelial cells and more inflammatory response in lung [6] . Many evidences have indicated that more apoptotic cells were exist in COPD lungs than normal control, while its nosogenesis remains unexplored [7] . He et al. found that cigarette smoke extract promoted human bronchial epithelial cells apoptosis [8] . However, few effective therapeutic targets of COPD were found, and it is crucial to explore the detailed mechanism of COPD.
Previous studies have been reported that many genes participated in the COPD progression, containing microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) [9] . LncRNA, a cluster of RNA transcripts with more than 200 nucleotides in length, were participated in mediating multiple cell physiological progress, including cell proliferation, apoptosis and migration [10] . In recent years, Li et al. found that lncRNA HEIH affected triple-negative breast cancer cells growth and apoptosis through regulating miR-4458/SOCS1 axis [11] . Wu et al. demonstrated that lncRNA ZEB2-AS1 regulates bladder cancer cell growth and apoptosis through miR-27b [12] . The lncRNA maternally expressed gene 3 (MEG3), one kind of lncRNA, is found to be a tumor inhibitor and existed in many normal organs [13] . Previous reports have illustrated that lncRNA MEG3 was over-expressed in many diseases, including, cancer retinopathy, osteoarthritis and cardiovascular disease [14] [15] [16] [17] . LncRNA MEG3 can regulate many types of cellular functions, including cell viability and apoptosis [16, 18, 19] . However, the interaction mechanism between lncRNA MEG3 and COPD need to be fully illuminated. Studies have revealed that human pulmonary microvascular endothelial cell (HPMEC) apoptosis is essential in the occurrence and development of COPD [20, 21] . Thus, we speculated that lncRNA MEG3 may play a key role in COPD through regulating HPMEC apoptosis.
In present report, we explored the function of lncRNA MEG3 in cigarette smoking extract (CSE)-stimulated HPMECs. We evaluated the effects of CSE on cell apoptosis, caspase-3 activity, apoptosis-related protein expression and lncRNA MEG3 levels in HPMECs. Our findings also demonstrated the mechanism of lncRNA MEG3-plasmid or lncRNA MEG3-shRNA (short hairpin RNA) in CSE-stimulated the apoptosis of HPMECs. In addition, we further elaborated the effects of lncRNA MEG3-shRNA on the influence of CSE in HPMECs. To conclude, our results demonstrated the protective function of lncRNA MEG3-shRNA in CSE-treated HPMECs, which may be an underlying target for COPD treatment in clinical.
Material and Methods

Cell culture
HPMECs, purchased from ATCC (Manassas, VA, USA), were cultivated in endothelial cell medium (Gibco, USA) containing 10% heated-inactivated fetal bovine serum (FBS, Gibco), 1% endothelial cell growth factor (Beyotime, China), 100 IU/mL penicillin and streptomycin (Sigma) at 37°C in a humidified atmosphere of 5% CO 2 .
Cigarette smoke extract (CSE) preparation and treatment
CSE was obtained using a modified method, as previously reported [22] . In brief, one commercial cigarette was burned with a reformative syringe-driven equipment. Then the smoke was bubbled in 20 mL medium at a speed of 100 mL/minute for more than 5 minutes. Thereafter, 0.2 μm pore membrane filter was conducted to eliminate big particulates from the resulting collection. This isolate was defined as "100% CSE".
The 100% CSE was diluted with phosphate-buffered saline (PBS), then HPMECs were treated with various concentration of CSE (0.1%, 1%, 10%) for 24 hours respectively [23] . Cells without any CSE treatment were regarded as the control group (Control).
Cell transfection
Synthetic control-plasmid (empty pcDNA3.1 vector; Shanghai GeneChem Co., Ltd.), lncRNA MEG3-plasmid (conducted refer to MEG3 sequence and then sub-cloned into the pcDNA3.1 vector; Shanghai GeneChem Co., Ltd.), control-shRNA (the scrambled shRNA plasmid; pGFP-C-shLenti Vector; cat. no. TR30021) and lncRNA MEG3-shRNA (sh-MEG3 sequence, 5'-GAGAGGTTGTTTCACTGGTATCTATTGCA-3'; pGFP-C-shLenti Vector; cat. no. TL 320132C) were obtained from OriGene. For transfection, HPMECs were incubated into 6-well plates and then transfected with control-plasmid, lncRNA MEG3plasmid, control-shRNA or lncRNA MEG3-shRNA respectively by Lipofectamine 2000 agentia (Beyotime) for 24 hours referring to the manufacturer's protocols.
Flow cytometry analysis
HPMECs were cultured in 6-well plates. After treatment, cells were obtained using EDTA-trypsin and washed with PBS.
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Then the Annexin V-FITC/propidium iodide (AV/PI) dual staining (Sigma, USA) was performed to determine the HPMECs cell apoptosis following the manufacturer's manual. The apoptotic cells were measured by FACS flow cytometer (BD Biosciences) and analyzed by the FlowJo software (Becton Dickinson, CA, USA).
Detection of caspase-3 activity
Caspase-3 Colorimetric Assay Kit (Beyotime, Shanghai, China) were used to assess the caspase-3 activity in HPMECs referring to the manufacturer's protocols. In a word, cells were dissolved with lysis buffer, and the supernatant of the lysate was gathered and centrifuged. Then the supernatant was cultured in Ac-DEVE-pNA and reaction buffer at 37°C for 2 hours. A microplate reader (BioTek, VT) was performed to detect optical density (OD) of caspase-3 activity at 405 nm.
Quantitative reverse transcription PCR (qRT-PCR) analysis
After indicated treatment, total RNA from HPMECs was obtained using RNA-isolation kit (Vazyme) referring to the manufacturer's protocol. RNA was reversely subjected to cDNA using the PrimeScipt RT reagent Kit (Takara, Shiga, Japan). The expression of relative genes was assessed by ABI 7500 Real-time PCR Detection System (Applied Biosystems, USA) with the SYBR Premix Ex Taq (Takara). Human 18srRNA was used as the internal inference for lncRNA. Primers were compounded by Sangon Biotech (Shanghai, China). Relative gene expression was analyzed using the 2 -DDCt method.
Western blot analysis
After indicated treatment, total proteins in HPMECs were obtained and extracted using radioimmunoprecipitation assay (RIPA) buffer (Sigma, USA) following the manufacturer's protocol. The lysates concentrations were evaluated by the bicinchoninic acid (BCA) Protein Assay Kit (Thermo). Then the protein extract was mingled with 5x loading buffer and separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by transferring to polyvinylidene difluoride (PVDF) membrane. After that, 5% fat-free milk was used to block membrane for 1.5 hour at room temperature, and cultivated overnight at 4°C with primary antibodies against Bax (Abcam, 1: 1000), Bcl-2 (Abcam, 1: 1000) and b-actin (1: 1500, Santa Cruz Biotechnology, Inc). The membrane was then washed with PBS with Tween (PBST) and incubated with secondary antibodies (1: 2000, Santa Cruz, USA) for 1 hour at 37°C. Finally, immunoreactive proteins were visualized by electrochemiluminescence (ECL) detection system (Bio Rad) according to the manufacturer's protocol and quantified with ImageJ Software.
Statistical analysis
GraphPad Prism 6.0 was conducted to evaluate the statistical analysis. All results were represented as means±standard deviation (SD) from 3 individual tests. Statistical comparisons were evaluated using unpaired Student t-test or one-way analysis of variance (ANOVA). * P<0.05 and ** P<0.01 were considered to indicate statistically significant difference.
Results
CSE stimulated cell apoptosis and enhanced lncRNA MEG3 expression in HPMECs
HPMECs were stimulated with 0.1%, 1%, and 10% CSE for 24 hours, then we assessed the effects of CSE on HPMECs. First, flow cytometry assay was employed to detect HPMEC apoptosis. Our results suggested that the cell apoptosis increased remarkably after CSE (0.1%, 1%, and 10%) treatment compared to the control group ( Figure 1A) . Moreover, the percentage of apoptotic HPMECs was increased in CSE-treated group compared to the control group ( Figure 1B) . Besides, we found the caspase-3 activity was significantly promoted after 0.1% CSE, 1% CSE, and 10% CSE treatment for 24 hours compared to that stimulated by 0% CSE ( Figure 1C ). Cell apoptosis often mediated by apoptosis-specific proteins, such as Bcl-2 and Bax. Thereafter, Bcl-2 and Bax levels in different groups was evaluated using western blot. As illustrated in Figure 1D , CSE exposure obviously enhanced the Bax expression level and induced a reduce in Bcl-2 in HPMECs. In order to expound the functions of lncRNA MEG3 in CSE-treated HPMECs, we first determined lncRNA MEG3 level by qRT-PCR analysis in CSEstimulated HPMECs. The results revealed that lncRNA MEG3 were apparently upregulated in HPMECs stimulated by 0.1% to 10% CSE ( Figure 1E ). No obvious difference was observed between 1% and 10% CSE-induced groups in aforementioned results; thus, we chose 1% CSE to induce cells for 24 hours in further experiments.
Over-expression of lncRNA MEG3 promoted HPMEC apoptosis
Previous results revealed that lncRNA MEG3 was upregulated in HPMECs. To lucubrate the potential mechanism of lncRNA MEG3 in cell apoptosis, control-plasmid or lncRNA MEG3plasmid was transfected into HPMECs for 24 hours. Transfection efficiency was evaluated using qRT-PCR. qRT-PCR analytical data revealed that lncRNA MEG3 was upregulated in lncRNA MEG3 plasmid treated HPMECs (Figure 2A) . The flow cytometry assay showed that lncRNA MEG3 over-expression increased apoptotic HPMECs remarkably and elevated the percentage of apoptotic cells compared with control group (Figure 2B, 2C ). 
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Furthermore, the caspase-3 activity assay showed that the caspase-3 activity was significantly increased in lncRNA MEG3 over-expressed HPMECs ( Figure 2D ). In summary, these data clarified that over-expression of lncRNA MEG3 could induce apoptosis in HPMECs.
Downregulation of lncRNA MEG3 inhibited apoptosis in HPMECs
For further exploration, we investigated the specific role of lncRNA MEG3 in HPMECs. Control-shRNA or lncRNA MEG3-shRNA were transfected into HPMECs. After transfection, lncRNA MEG3 levels in HPMECs was determined by qRT-PCR. We found that lncRNA MEG3 level was dramatically decreased in HPMECs after lncRNA MEG3-shRNA transfection compared to control ( Figure 3A ). In addition, flow cytometry results revealed that lncRNA MEG3-shRNA-treated HPMECs revealed a significantly decrease in apoptosis and apoptotic cell rate ( Figure 3B, 3C) . Likewise, compared to the control group, knockdown of MEG3 obviously suppressed the caspase-3 activity in lncRNA MEG3-shRNA-treated HPMECs ( Figure 3D ). These data clarified that lncRNA MEG3 might be participated in mediating HPMEC apoptosis.
LncRNA MEG3-shRNA relieved the influence of CSE on HPMECs
To deeply explore the role of lncRNA MEG3-shRNA in the CSEinduced HPMECs, control-shRNA or lncRNA MEG3-shRNA were transfected into HPMECs for 24 hours, followed by 1% CSE 
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treatment for another 24 hours. As shown in Figure 4A , the level of lncRNA MEG3 significantly enhanced in CSE-stimulated HPMECs compared to the control group. However, compared with CSE+control-shRNA group, the level of lncRNA MEG3 was significantly depressed in CSE+lncRNA MEG3-shRNA group. Besides, HPMEC apoptosis was detected and the apoptosis rate was also quantified in different groups. More apoptotic cells were found in CSE-treated HPMECs, and the apoptotic rate of HPMECs was higher in the 1% CSE treatment group compared to the control group. while lncRNA MEG3-shRNA significantly inhibited HPMEC apoptosis ( Figure 4B, 4C) . Furthermore, the effect of 1% CSE on caspase-3 activity and apoptosis-related proteins levels were also detected in different groups. Our results revealed that 1% CSE significantly promoted the caspase-3 activity ( Figure 4D ), decreased Bcl-2 and increased the Bax expression levels ( Figure 4E ). Conversely, lncRNA MEG3-shRNA reversed all these effects of 1% CSE on caspase-3 activity and apoptosis-related genes expression. In summary, these results indicated that lncRNA MEG3-shRNA could reverse the cell apoptosis in CSE-induced HPMECs, indicting lncRNA MEG3 might be a novel target for COPD treatment. 
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Discussion COPD, the fourth primary factor of death around the world, is a chronic disease with poor survival prognosis [24] [25] [26] . Evidence showed that cigarette smoking is main hazards in COPD progression, and it could regulate various cells apoptosis including lung epithelial cells and vascular endothelial cells [27, 28] . Besides, previous reports delineated that increased apoptosis was observed both in COPD patients and animal models [29, 30] . Thus, in our experiments, we sought to determine the role of CSE in HPMEC apoptosis. Our results suggested that different CSE (0.1%, 1%, 10%) obviously promoted HPMECs apoptosis. As we all know, cell apoptosis is associated with several cascade proteins and apoptosis-related proteins [31] . Consistent with this concept, we detected the caspase-3 activity and the members of Bax and Bcl-2 family protein levels. We found that CSE increased caspase-3 activity, enhanced Bax levels and reduced Bcl-2 expression in HPMECs, especially at the concentration of 1%.
Numerous scientific evidences have indicated that lncRNAs are upregulation in multiple diseases, including Alzheimer's disease [32] , coronary artery disease [33] and lung cancer [34] , but the relevance between lncRNA and COPD need to be further illustrated. LncRNA MEG3, a new element of lncRNA, is identified as a regulator in cell biological behavior [35] and widely 
e920793-6
involved in many diseases [14] [15] [16] [17] . For example, Zhang et al. found lncRNA MEG3 suppressed cell EMT through sponging miR-421 targeting E-cadherin in breast cancer [36] . Besides, Kruer et al. have reported that lncRNA MEG3 abnormal expression may affected lung cancer cell growth via Rb pathway [37] . In this research, these results indicated that CSE upregulated the lncRNA MEG3 expression in HPMECs.
Precious evidences have confirmed that lncRNA was dysregulated in many diseases, including COPD [38, 39] . As human pulmonary microvascular endothelial cell apoptosis is essential in the progression of COPD [20, 21] , we then attempted to investigate the effects of lncRNA MEG3 on the apoptosis of HPMECs. Many studies have explored the pathogenesis of COPD in vitro by studying the apoptosis of HPMECs [20, 21, 23] . Consistent with the previous findings [23] , the data of the current study indicated that 1% CSE significantly induced apoptosis in HPMECs. In addition, the functional assay demonstrated that the upregulation of lncRNA MEG3 resulted in more apoptotic HPMECs, and higher caspase-3 activity in HPMECs. While lncRNA MEG3-shRNA led to fewer apoptotic HPMECs, and lower caspase-3 activity in HPMECs. These results demonstrated e920793-7 that lncRNA MEG3 played a vital role in COPD through regulating HPMEC apoptosis.
Furthermore, we then verified whether CSE promoted apoptosis in HPMECs by upregulating lncRNA MEG3, and rescue experiments were performed. The results revealed that the increased lncRNA MEG3 level, enhanced cell apoptosis, upregulated caspase-3 activity, reduced Bcl-2 level and enhanced Bax expression in HPMECs were significantly eliminated by lncRNA MEG3-shRNA.
All in all, these results evidenced that lncRNA MEG3 was participated in the evolution of COPD and might be strongly associated with cell apoptosis in HPMECs. Moreover, this study confirmed that lncRNA MEG3 might be an underlying target for COPD therapy. However, we only investigated the function of lncRNA MEG3 in CSE-induced HPMECs in vitro model, more valid animal models need to be designed in future investigation.
Conclusions
LncRNA MEG3 is participated in the evolution of COPD through regulating cell apoptosis of HPMECs. LncRNA MEG3 may be an underlying target for COPD therapy.
